Aberrant responses of human lymphocytic neoplasms to cytokine regulation

Immunologic Research

Volumn 17, Issue 1-2, 1998, Pages 171-177

  Nowell, Peter C ^a   Moore, Jonni S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Cytokines; TGF beta

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMMUNOREGULATION; PRIORITY JOURNAL; SEZARY SYNDROME; T LYMPHOCYTE;

EID: 0031918987     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786442     Document Type: Article

References (38)

1. Nowell PC: Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Cancer Genet Cytogenet 1997;94:13-20.
2. Moore JS, Friedman DF, Silberstein LE, Besa EC, Nowell PC: Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1995;20:141-164.
3. Marks DI, Vonderheid EC, Kurz BW, Bigler RD, Sinha K, Morgan DA, et al.: Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome. Br J Haematol 1996;92:890-899.
4. Thangavelu M, Finn WG, Yelavarthi KK, Roenigk HH, Samuelson E, Peterson LA, et al.: Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood 1997;89:3371-3377.
5. Kerhl JH, Roberts AB, Wakefield LM, Jakowlew SB, Sporn MB, Fauci AS: Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137:3855-3859.
6. Wahl SM, Hunt DA, Wong HL, Doughert S, McCartney-Francis N, Wahl LM, et al.: Transforming growth factor beta is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation. J Immunol 1988;140:3026-3030.
7. Chaouchi N, Arvanitakis L, Auffredou MT, Blanchard DA, Vazquez A, Sharma S: Characterization of transforming growth factor-beta-1 induced apoptosis in normal human B-cells and lymphoma B-cell lines. Oncogene 1995;11:1615-1620.
8. Trentin L, Cerutti A, Zambello R, Sancetta R, Tassinari C, Facco M, et al.: Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996;87: 3327-3335.
9. Osario LM, De Santiago A, Aguilar-Santalises M, Mellstedt H, Jondal M: CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B-cells from apoptosis induced by anti-IgM. Blood 1997;89:2833-2841.
10. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf SF, Singh A, Trinchieri G, Lessin SR: IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491-1498.
11. McCusker ME, Garifallou M, Bogen SA: Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. J Immunol 1997;158:4984-4991.
12. Mauer AM: Clinical features of human leukemia; in Mauer AM (ed): The Biology of Human Leukemia. Baltimore, Johns Hopkins University Press, 1990, pp 1-27.
13. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS: Chronic lymphocytic leukemia B-cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood; 1997;89:941-947.
14. Kremer JP, Reisbach G, Nerl C, Dormer P: B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta. Br J Haematol 1992;80: 480-489.
15. Lotz M, Raanhein E, Kipps T: Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B-cells. J Exp Med 1994;179:999-1008.
16. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, et al.: Loss of functional cell surface transforming growth factor beta (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94:5877-5881.
17. Phillips JA, Mehta K, Fernandez C, Raveche ES: The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 1992; 52:437-443.
18. Phillips J, Raveche E: Immunoregulatory capability of murine CLL-like CD5+ B-cells. Ann NY Acad Sci 1992;651:488-490.
19. Raveche ES, Lalor P, Stall A, Conroy J: In vivo effects of hyperdiploid Ly-1+ B-cells of NZB origin. J Immunol 1988;141:4133-4139.
20. Douglas RS, Woo EY, Capocasale RJ, Tarshis AD, Nowell PC, Moore SJ: Altered response to and production of TGF-ß by B-cells from autoimmune NZB mice. Cell Immunol 1997;179:126-131.
21. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin-4 protects chronic lymphocytic leukemia from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-1329.
22. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV: IL-4 inhibits apoptotic cell death and loss of the Bcl-2 protein in B-CLL cells in vitro. Br J Haematol 1993; 85:439-451.
23. Moore JS, Zaki M, Douglas R, Nowell P: Altered cytokine production by T cells from patients with B-CLL (Abstract). Cytometry 1997, in press.
24. Buschle M, Campana D, Carding S, Richard C, Hoffbrand AV, Brenner MK: Interferon-gamma inhibits apoptotic cell death in B-cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-218.
25. Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ: Autoantigen inhibits apoptosis of a human B-cell leukemia that produces pathogenic rheumatoid factor. J Immunol 1993;151:7273-7283.
26. Rabbitts T: Translocations, master genes and differences between the origins of acute and chronic leukemias. Cell 1991;67:641-653.
27. Kitada S, Bullrich F, Krajewski S, Zapata J, Andersen J, Hines J, et al.: Bcl-2 family genes, CPP32 protease, 13q14 deletions, and in vitro sensitivity to fludarabine and 2-chlorodeoxyadenosine in B-CLL: an ECOG study [Abstract]. Proc Am Assoc Cancer Res 1997;38:169.
28. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, et al.: Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood 1997;89:3817-3825.
29. Karras JG, Wang Z, Huo L, Howard RG, Frank DA, Rothstein TL: Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med. 1997;185:1035-1042.
30. Bellosillo B, Dalmau M, Colomer D, Gil J: Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997;89:3378-3384.
31. Sterry W, Mielke V: CD4+ cutaneous T cell lymphomas show the phenotype of helper/inducer T-cells (CD45RA-,CDw29+). J Invest Dermatol 1989;93:413-416.
32. Heald P, Yan S-L, Edelson R: Profound deficiency in normal circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 1994;130:198-203.
33. Bogen SA, Pelley D, Charif M, McCusker M, Koh H, Foss F, et al.: Immunophenotypic identification of Sezary's cells in peripheral blood. Am J Clin Pathol 1996; 106:739-747.
34. Edelson RL: Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 1980;2:89:106.
35. Capocasale RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC, et al.: Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T-cells from Sézary patients. Proc Natl Acad Sci USA 1995;92:5501-5505.
36. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D: Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994;91:6002-6006.
37. Myeroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, et al.: A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-5547.
38. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al.: Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996;93:9148-9153.